Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

Market Cap	7.85B +21.1%
Revenue (ttm)	794.80M -0.8%
Net Income	108.03M -49.4%
EPS	0.13 -47.2%
Shares Out	825.10M
PE Ratio	70.83
Forward PE	28.82
Dividend	0.06 (0.67%)
Ex-Dividend Date	Jul 17, 2025

Volume	12,944,268
Open	9.47
Previous Close	9.51
Day's Range	9.32 - 9.70
52-Week Range	8.32 - 12.51
Beta	-0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About SHA:603229

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 1,328
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603229

Financial Performance

In 2025, SHA:603229's revenue was 792.76 million, a decrease of -0.32% compared to the previous year's 795.29 million. Earnings were 130.57 million, a decrease of -36.86%.